CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

We determined the prognostic relevance of CD25 (IL-2 receptor-α) expression in 657 patients (≤ 60 years) with de novo acute myeloid leukemia (AML) treated in the Eastern Cooperative Oncology Group trial, E1900. We identified CD25(POS) myeloblasts in 87 patients (13%), of whom 92% had intermediate-ri...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Gönen, Mithat, Sun, Zhuoxin, Figueroa, Maria E., Patel, Jay P., Abdel-Wahab, Omar, Racevskis, Janis, Ketterling, Rhett P., Fernandez, Hugo, Rowe, Jacob M., Tallman, Martin S., Melnick, Ari, Levine, Ross L., Paietta, Elisabeth
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2012
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3447784/
https://ncbi.nlm.nih.gov/pubmed/22855599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-414425
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items